AnaptysBio
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AnaptysBio and other ETFs, options, and stocks.About ANAB
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab.
ANAB Key Statistics
Stock Snapshot
As of today, AnaptysBio(ANAB) shares are valued at $40.00. The company's market cap stands at 1.1B, with a P/E ratio of -14.05.
As of 2025-11-23, AnaptysBio(ANAB) stock has fluctuated between $32.22 and $40.12. The current price stands at $40.00, placing the stock +24.1% above today's low and -0.3% off the high.
The AnaptysBio(ANAB)'s current trading volume is 1.53M, compared to an average daily volume of 1M.
During the past year, AnaptysBio(ANAB) stock moved between $12.21 at its lowest and $40.96 at its peak.
During the past year, AnaptysBio(ANAB) stock moved between $12.21 at its lowest and $40.96 at its peak.
ANAB News
TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...
AnaptysBio (ANAB) announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that Tesaro has materially breached the...
AnaptysBio (ANAB) announced that its board of directors has authorized an amended stock repurchase plan under which the company may repurchase up to $100M of th...
Analyst ratings
92%
of 12 ratingsMore ANAB News
(RTTNews) - AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, on Friday said its Board has approved an amended stock repurchase plan allowing the...
(RTTNews) - GSK plc (GSK), a biopharmaceutical company's subsidiary Tesaro, Inc. (TSRO), on Friday announced that it has filed litigation in the Delaware Chance...
AnaptysBio (ANAB) just shared results from its Phase 2 study of rosnilimab in moderate to severe ulcerative colitis. The drug was safe but failed to hit key eff...
